(Total Views: 221)
Posted On: 10/06/2022 3:35:51 PM
Post# of 61

$GALT News Article - Galectin Therapeutics Reports the Positive Outcome of the Second Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis https://marketwirenews.com/news-releases/gale...34877.html


My Twitter: WhyteStocks